宏利红利先锋混合A：2025年第二季度利润94.2万元 净值增长率1.98%

Core Viewpoint - The AI Fund Manulife Dividend Pioneer Mixed A (162212) reported a profit of 942,000 yuan for Q2 2025, with a weighted average profit per fund share of 0.0171 yuan, and a net value growth rate of 1.98% during the reporting period [3][17]. Fund Performance - As of July 18, the fund's unit net value was 0.989 yuan, with a one-year cumulative growth rate of 8.09%, ranking 127 out of 133 comparable funds [3][4]. - The fund's three-month cumulative growth rate was 12.64%, ranking 119 out of 138 comparable funds, and the six-month growth rate was 10.13%, ranking 132 out of 138 [4]. Investment Strategy - The fund focuses on long-term investments in pharmaceutical and medical stocks, targeting companies with sustainable dividend capabilities and strong fundamentals [3]. - As of Q2 2025, the fund's main investments were concentrated in sectors such as in-hospital medical devices, equipment and consumables, in-hospital pharmaceuticals, and medical consumer products [3]. Risk Metrics - The fund's three-year Sharpe ratio was -0.0246, ranking 61 out of 105 comparable funds [10]. - The maximum drawdown over the past three years was 27.61%, with the largest single-quarter drawdown occurring in Q1 2022 at 21.42% [12]. Fund Composition - As of Q2 2025, the fund's total assets amounted to 50.68 million yuan [17]. - The top ten holdings included companies such as Aohua Endoscopy, Huatai Medical, and Heng Rui Medicine [19]. Portfolio Management - The fund has maintained a high average stock position of 92.95% over the past three years, compared to a comparable average of 86.95% [15].